Cantor Fitzgerald has initiated coverage of Celgene Corp. (CELG, Financial) with an overweight rating. The analyst established a price target of $100 per share, which represents an 11.3% upside from the share price of $89.88 at close Monday.
The stock has fallen 38% during 52 weeks of trading. It is trading below the 100-day simple moving average line and on par with the 50- and 200-SMA lines.
The 52-week range is $74.13 to $146.89 per share. The stock has a market capitalization of $63.2 billion, a price-book ratio of 18.41 versus an industry median of 4.1, a price-sales ratio of 4.93 and a price-earnings of 24.69 versus an industry median of 28.79.
The share price is above the Peter Lynch Earnings Line (P/E = 15).
Celgene Corp. has an average target price of $111.94 and a recommendation rating of 2.2 out of 5.
The forward price-earnings ratio is 8.53. Analysts predict earnings per share of $8.76 for fiscal 2018 and $10.62 for fiscal 2019.
The company is not paying dividends.
GuruFocus assigns Celgene Corp. a financial strength rating of 5 out of 10 and a profitability and growth rating of 8 out of 10.
The analyst has started covering Regeneron Pharmaceuticals Inc. (REGN, Financial) with a neutral rating. The analyst has set a price target of $415 per share, which represents 5.3% upside from the share price of $394.23 at close Monday.
The stock is down 13% during the last 52 weeks. The current share price is above the 200-, 100- and 50-day simple moving average lines.
The stock has a market capitalization of $42.6 billion. The share price falls in the 52-week range of $281.89 to $477 per share. The price-book ratio is 5.92 versus an industry median of 4.1, the price-sales ratio is 7.34 and the price-earnings ratio is 28.57 versus an industry median of 28.79.
The stock has an average target price of $406.76 per share and a recommendation rating of 2.6 out of 5.
The share price is above the Peter Lynch Earnings Line (P/E = 15).
The company is not paying dividends.
The forward price-earnings ratio is 18.35. Analysts predict earnings per share of $20.41 for fiscal 2018 and $22 for fiscal 2019.
GuruFocus assigns Regeneron Pharmaceuticals a financial strength rating of 8 out of 10 and a profitability and growth rating of 8 out of 10.
Cantor Fitzgerald has initiated coverage of Vertex Pharmaceuticals Inc. (VRTX, Financial) with an overweight rating. The analyst established a price target of $217 per share, which represents a 13.3% upside from the share price of $191.57 at close Monday.
The stock has climbed 26% for the 52 weeks through Oct. 1. It is trading above the 50-, 100 and 200-SMA lines.
The 52-week range is $136.5 to $194.92 per share. The stock has a market capitalization of $48.96 billion, a price-book ratio of 18.18 versus an industry median of 4.1, a price-sales ratio of 18.71 and a price-earnings of 119.73 versus an industry median of 28.79.
The share price is above the Peter Lynch Earnings Line (P/E = 15).
The recommendation rating is 1.8 out of 5 and the average target price is $197.45 per share.
The company is not paying dividends.
The forward price-earnings ratio is 40.65. Analysts predict earnings per share of $3.76 for fiscal 2018 and $4.64 for fiscal 2019.
GuruFocus assigns Vertex Pharmaceuticals a financial strength rating of 7 out of 10 and a profitability and growth rating of 6 out of 10.
The firm has initiated coverage of Biogen Inc. (BIIB, Financial) with an overweight rating and a price target of $400 per share. The price target of Cantor represents a 13.5% upside from the share price of $352.56 at close Monday.
The stock has grown 11% for the 52 weeks through Oct. 1. It is trading above the 200-, 100- and 50-SMA lines.
The 52-week range is $249.17 to $388.67 per share. The stock has a market capitalization of $71.02 billion, a price-book ratio of 5.79 versus an industry median of 4.1, a price-sales ratio of 5.77 and a price-earnings of 24.95 versus an industry median of 28.79.
The share price is above the Peter Lynch Earnings Line (P/E = 15).
The recommendation rating is 2 out of 5 and the average target price is $393.48 per share.
The company is not paying dividends.
The forward price-earnings ratio is 13.61. Analysts predict earnings per share of $25.33 for fiscal 2018 and $27.37 for fiscal 2019.
GuruFocus assigns Biogen Inc. a financial strength rating of 7 out of 10 and a profitability and growth rating of 10 out of 10.
Cantor Fitzgerald has started covering Amgen (AMGN, Financial) with a neutral rating and a price target of $223 per share. The price target of Cantor represents a 7.8% upside from the share price of $206.91 at close Monday.
The stock has grown 11% for the 52 weeks through Oct. 1. It is trading above the 200-, 100- and 50-SMA lines.
The 52-week range is $163.31 to $210.19 per share. The stock has a market capitalization of $133.93 billion, a price-book ratio of 9.01 versus an industry median of 4.1, a price-sales ratio of 6.3 and a price-earnings of 56.23 versus an industry median of 28.79.
The share price is above the Peter Lynch Earnings Line (P/E = 15).
The recommendation rating is 2.3 out of 5. The average target price is $205 per share.
The company is distributing dividends. If the cash quarterly dividend of $1.32 is held constant, it leads to a forward annual dividend of $5.28, granting 2.55%. The forward dividend yield of Amgen is above the 1.74% dividend yield of the S&P 500 index and above the 2.49% yield on one-Year U.S. Treasury bills.
The forward price-earnings ratio is 14.49. Analysts predict earnings per share of $13.99 for fiscal 2018 and $14.56 for fiscal 2019.
GuruFocus assigns Amgen a financial strength rating of 5 out of 10 and a profitability and growth rating of 8 out of 10.
Disclosure: I have no positions in any security mentioned in this article.
